会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 41. 发明申请
    • EPHA2, EPHA4 AND LMW-PTP AND METHODS OF TREATMENT OF HYPERPROLIFERATIVE CELL DISORDERS
    • EPHA2,EPHA4和LMW-PTP及治疗高增殖性细胞病的方法
    • WO2005055948A3
    • 2006-11-09
    • PCT/US2004041023
    • 2004-12-06
    • MEDIMMUNE INCKINCH MICHAEL S
    • KINCH MICHAEL S
    • A61K38/00A61K20060101A61K9/127A61K39/395A61K48/00
    • A61K38/1709A61K9/127A61K48/00A61K2039/505C07K16/2866C07K2317/56C07K2317/565C07K2317/622C12N9/12C12N9/16C12Y301/03048
    • The present invention relates to methods and compositions designed for treatment, management, or prevention of a hyperproliferative cell disease, particular cancer. The methods of the invention comprise the administration of an effective amount of a composition that targets cells expressing low molecular weight protein tyrosine kinase ("LMW-PTP") in particular using moieties that bind an Eph family receptor tyrosine kinase, such as EphA2 or EphA4, and inhibits or reduces LMW-PTP expression and/or activity. In i one embodiment, the method of the invention comprises administering to a subject a composition comprising an EphA2 or EphA4 targeting moiety attached to a delivery vehicle, and one or more agents that inhibit LMW-PTP expression and/or activity operatively associated with the delivery vehicle. In another embodiment, the method of the invention comprises administering to a subject a composition comprising a nucleic acid comprising a nucleotide sequence encoding an EphA2 or EphA4 targeting moiety and an agent that inhibits or reduces LMW-PTP expression and/or activity. In yet another embodiment, the method of the invention comprises administering to a subject a composition comprising an EphA2 or EphA4 targeting moiety and a nucleic acid comprising a nucleotide sequence encoding an agent that inhibits or reduces LMW-PTP expression and/or activity, where the nucleic acid is operatively associated with the delivery vehicle. Pharmaceutical compositions are also provided by the present invention.
    • 本发明涉及用于治疗,治疗或预防过度增殖性细胞疾病,特定癌症的方法和组合物。 本发明的方法包括施用有效量的靶向表达低分子量蛋白酪氨酸激酶(“LMW-PTP”)的细胞的组合物,特别是使用结合Eph家族受体酪氨酸激酶(例如EphA2或EphA4)的部分 ,并且抑制或降低LMW-PTP表达和/或活性。 在一个实施方案中,本发明的方法包括向受试者施用包含与递送载体​​连接的EphA2或EphA4靶向部分的组合物,以及一种或多种抑制LMW-PTP表达和/或与递送有效相关的活性的试剂 车辆。 在另一个实施方案中,本发明的方法包括向受试者施用包含核酸的组合物,所述核酸包含编码EphA2或EphA4靶向部分的核苷酸序列和抑制或降低LMW-PTP表达和/或活性的试剂。 在另一个实施方案中,本发明的方法包括对受试者施用包含EphA2或EphA4靶向部分的组合物和包含编码抑制或降低LMW-PTP表达和/或活性的试剂的核苷酸序列的核酸,其中 核酸与递送载体​​可操作地相关联。 药物组合物也由本发明提供。
    • 44. 发明申请
    • EPHA2, HYPOPROLIFERATIVE CELL DISORDERS AND EPITHELIAL AND ENDOTHELIAL RECONSTITUTION
    • EPHA2,HYPOPROLIFERATIVE CELL DISORDERS AND EPITHELIAL AND ENDOTHELIAL RECONSTITUTION
    • WO2004092343A3
    • 2005-12-01
    • PCT/US2004011481
    • 2004-04-12
    • MEDIMMUNE INCKIENER PETER AKINCH MICHAEL SLANGERMANN SOLOMON
    • KIENER PETER AKINCH MICHAEL SLANGERMANN SOLOMON
    • A61K38/00A61K38/19A61K39/395A61K48/00C07K14/715C07K16/28C12N20060101
    • C07K16/2866A61K38/19C07K14/715
    • The present invention relates to methods and compositions designed for the treatment, management, or prevention of a hypoproliferative cell disorder, especially those disorders relating to the destruction, shedding, or inadequate proliferation of epithelial and/or endothelial cells, particularly interstitial cystitis (IC) and lesions associated with inflammatory bowel disease (IBD). The methods of the invention comprise the administration of an effective amount of one or more agents that are antagonists of EphA2. In certain embodiments, the EphA2 antagonistic agent of the invention decreases EphA2endogenous ligand binding, upregulates EphA2 gene expression and/or translation, increases EphA2 protein stability or protein accumulation, decreases EphA2 cytoplasmic tail phosphorylation, promotes EphA2 kinase activity (other than autophosphorylation or ligandmediated EphA2 signaling), increases proliferation of EphA2 expressing cells, increases survival of EphA2 expressing cells, and/or maintains/reconstitutes epithelial and/or endothelial cell layer integrity. The invention also provides pharmaceutical compositions comprising one or more EphA2 antagonistic agents of the invention either alone or in combination with one or more other agents useful for therapy for a hypoproliferative cell disorder. Diagnostic methods and methods for screening for therapeutically useful agents are also provided.
    • 本发明涉及设计用于治疗,治疗或预防低增殖性细胞病症的方法和组合物,特别是与上皮和/或内皮细胞,特别是间质性膀胱炎(IC)的破坏,脱落或不充分增殖有关的那些疾病, 和与炎症性肠病(IBD)相关的损伤。 本发明的方法包括施用有效量的一种或多种作为EphA2拮抗剂的试剂。 在某些实施方案中,本发明的EphA2拮抗剂降低EphA2内源性配体结合,上调EphA2基因表达和/或翻译,增加EphA2蛋白稳定性或蛋白质积累,降低EphA2胞质尾磷酸化,促进EphA2激酶活性(除了自磷酸化或配体介导的EphA2 增加EphA2表达细胞的增殖,增加EphA2表达细胞的存活,和/或维持/重建上皮和/或内皮细胞层完整性。 本发明还提供包含本发明的一种或多种EphA2拮抗剂的药物组合物,其单独或与一种或多种其它用于治疗低增殖性细胞病症的其它药剂组合。 还提供了用于筛选治疗有用的药剂的诊断方法和方法。
    • 45. 发明申请
    • EPHA2 VACCINES
    • EPHA2疫苗
    • WO2005067460A2
    • 2005-07-28
    • PCT/US2004/034693
    • 2004-10-15
    • MEDIMMUNE, INC.KINCH, Michael, S.
    • KINCH, Michael, S.
    • A61K39/00
    • A61K39/0011A61K47/6425A61K47/644A61K47/6901A61K2035/122A61K2039/52A61K2039/523A61K2039/5256A61K2039/53A61K2039/6043A61K2039/6056
    • The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly metastatic cancer, and hyperproliferative diseases involving EphA2-expressing cells. In one embodiment, the methods of the invention comprise the administration of an effective amount of an EphA2 antigenic peptide to elicit an immune response against the EphA2-expressing cells. In other embodiments, the methods of the invention entail the use of an EphA2 expression vehicle, such as a naked nucleic acid or viral vector. In yet other embodiments, the methods of the invention comprise the use of adoptive immunotherapy with autologous or non-autologous antigen presenting cells that are sensitized with one or more EphA2 antigenic peptides. The invention also provides pharmaceutical compositions comprising one or more EphA2 antigenic peptides, expression vehicles or antigen-presenting cells of the invention either alone or in combination with one or more other agents useful for cancer therapy.
    • 本发明涉及设计用于治疗,管理或预防癌症,特别是转移性癌症和涉及EphA2表达细胞的过度增殖性疾病的方法和组合物。 在一个实施方案中,本发明的方法包括施用有效量的EphA2抗原肽以引发针对EphA2表达细胞的免疫应答。 在其它实施方案中,本发明的方法需要使用EphA2表达载体,例如裸核酸或病毒载体。 在其它实施方案中,本发明的方法包括使用与一种或多种EphA2抗原肽致敏的自体或非自体抗原呈递细胞的过继免疫治疗。 本发明还提供包含本发明的一种或多种EphA2抗原肽,表达载体或抗原呈递细胞的药物组合物,其单独或与一种或多种其它可用于癌症治疗的试剂组合。
    • 46. 发明申请
    • EPHA2 AND HYPERPROLIFERATIVE CELL DISORDERS
    • EPHA2和高增殖性细胞病变
    • WO2004091375A2
    • 2004-10-28
    • PCT/US2004/011482
    • 2004-04-12
    • MEDIMMUNE, INC.KIENER, Peter, A.KINCH, Michael, S.LANGERMANN, SolomonREED, Jennifer, L.
    • KIENER, Peter, A.KINCH, Michael, S.LANGERMANN, SolomonREED, Jennifer, L.
    • A61B
    • C07K16/28A61K2039/505C07K16/32
    • The present invention relates to methods and compositions designed for the treatment, management, or prevention of a non-neoplastic hyperproliferative cell or excessive cell accumulation disorders, particularly those involving hyperproliferation of epithelial or endothelial cells. In one embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and increase EphA2 cytoplasmic tail phosphorylation and/or increase EphA2 autophosphorylation. in cells which EphA2 has been agonized. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and reduce EphA2 activity (other than autophosphorylation). In another embodiment, the methods of the invention comprise administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and decrease a pathology-causing cell phenotype ( e.g ., a pathology-causing epithelial cell phenotype or a pathology-causing endothelial cell phenotype). In another embodiment, the methods of the invention comprise the administration of an effective amount. of one or more EphA2 agonistic agents that are EphA2 antibodies that bind to EphA2 with a very low K off rate. In prefer-red embodiments, agents of the invention are inonoclonal antibodies. The invention also provides pharmaceutical compositions comprising one or more EphA2 agonistic agents of the invention either alone or in combination with one or more other agents useful in therapy for non-neoplastic hyperproliferative cell or excessive cell accumulation disorders.
    • 本发明涉及设计用于治疗,管理或预防非肿瘤性过度增殖性细胞或过度细胞累积障碍,特别是涉及上皮细胞或内皮细胞过度增殖的方法和组合物。 在一个实施方案中,本发明的方法包括施用有效量的一种或多种结合EphA2并增加EphA2细胞质尾磷酸化和/或增加EphA2自磷酸化的EphA2激动剂。 在EphA2被激活的细胞中。 在另一个实施方案中,本发明的方法包括施用有效量的一种或多种EphA2激动剂,其结合EphA2并降低EphA2活性(除了自磷酸化)。 在另一个实施方案中,本发明的方法包括施用有效量的一种或多种结合EphA2的EphA2激动剂并减少病理学引起的细胞表型(例如,导致病理的上皮细胞表型或致病性病因的内皮 细胞表型)。 在另一个实施方案中,本发明的方法包括施用有效量。 的一种或多种EphA2激动剂,其是以非常低的Koff率与EphA2结合的EphA2抗体。 在优选的实施方案中,本发明的试剂是异源抗体。 本发明还提供包含本发明的一种或多种EphA2激动剂的药物组合物,其单独或与一种或多种其它可用于治疗非肿瘤性过度增殖性细胞或过度细胞累积障碍的其它药物组合。